Author:
Rosenbloom Michael H.,O’Donohue Tricia,Zhou-Clark Domi,Mala Deepashni,Frazier Andrew,Tarrant Michael,Modrijan Michelle,Riveira Melora,Chapman Darla,Griffin Yvonne,Shakalis Lauren,Grabowski Thomas J.
Publisher
Springer Science and Business Media LLC
Reference12 articles.
1. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10:362–77.
2. 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023;19:1598–695.
3. Pittock RR, Aakre JA, Castillo AM, et al. Eligibility for anti-amyloid treatment in a population-based study of cognitive aging. Neurology. 2023;101:e1837–49.
4. Wolk DA, Rabinovici GD, Dickerson BC. A step forward in the fight against dementia—are we there yet? JAMA Neurol. 2023;80:429–30.
5. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21.